CY1116275T1 - Νεα αντιμυκητιακη συνθεση - Google Patents

Νεα αντιμυκητιακη συνθεση

Info

Publication number
CY1116275T1
CY1116275T1 CY20151100425T CY151100425T CY1116275T1 CY 1116275 T1 CY1116275 T1 CY 1116275T1 CY 20151100425 T CY20151100425 T CY 20151100425T CY 151100425 T CY151100425 T CY 151100425T CY 1116275 T1 CY1116275 T1 CY 1116275T1
Authority
CY
Cyprus
Prior art keywords
composition
antificial
new
pharmaceutical composition
diol
Prior art date
Application number
CY20151100425T
Other languages
Greek (el)
English (en)
Inventor
Åke Lindahl
Original Assignee
Moberg Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45581892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116275(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Moberg Pharma Ab filed Critical Moberg Pharma Ab
Publication of CY1116275T1 publication Critical patent/CY1116275T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CY20151100425T 2011-02-11 2015-05-13 Νεα αντιμυκητιακη συνθεση CY1116275T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1150107 2011-02-11
EP12703537.6A EP2672962B1 (en) 2011-02-11 2012-02-10 Novel antifungal composition

Publications (1)

Publication Number Publication Date
CY1116275T1 true CY1116275T1 (el) 2017-02-08

Family

ID=45581892

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100425T CY1116275T1 (el) 2011-02-11 2015-05-13 Νεα αντιμυκητιακη συνθεση

Country Status (24)

Country Link
US (3) US8952070B2 (enExample)
EP (1) EP2672962B1 (enExample)
JP (1) JP5883886B2 (enExample)
KR (1) KR101647545B1 (enExample)
CN (2) CN109453150A (enExample)
AU (1) AU2012215383B2 (enExample)
BR (1) BR112013020456B1 (enExample)
CA (1) CA2826741C (enExample)
CY (1) CY1116275T1 (enExample)
DK (1) DK2672962T3 (enExample)
ES (1) ES2535827T3 (enExample)
HR (1) HRP20150507T1 (enExample)
IL (1) IL227765A (enExample)
ME (1) ME02152B (enExample)
MX (1) MX335945B (enExample)
PL (1) PL2672962T3 (enExample)
PT (1) PT2672962E (enExample)
RS (1) RS53982B1 (enExample)
RU (1) RU2587064C2 (enExample)
SG (1) SG192615A1 (enExample)
SI (1) SI2672962T1 (enExample)
SM (1) SMT201500154B (enExample)
WO (1) WO2012107565A1 (enExample)
ZA (1) ZA201305891B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2672962T3 (pl) 2011-02-11 2015-08-31 Moberg Pharma Ab Nowa kompozycja przeciwgrzybicza
CN103415824B (zh) 2012-08-30 2015-04-08 华为终端有限公司 一种控制中央处理器的方法和装置
US10272054B2 (en) * 2015-10-07 2019-04-30 Exodos Life Sciences Lp Topical antifungal compositions
US10258560B1 (en) 2016-08-08 2019-04-16 Marlinz Pharma, LLC Composition for topical treatment of nail conditions
US10543276B2 (en) 2016-08-08 2020-01-28 Marlinz Pharma, LLC Topical compositions
EP3292758A1 (en) 2016-09-07 2018-03-14 Rottapharm S.p.A. Antimicrobial composition comprising a carboxylic acid and two diols
WO2019206389A1 (en) * 2018-04-27 2019-10-31 Unigroup Aps Kit of parts for nail fungus
US11576920B2 (en) 2019-03-18 2023-02-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
KR20230116911A (ko) * 2020-12-08 2023-08-04 모베르그 파르마 아베 알릴아민 항진균 조성물을 사용한 조갑진균증의 치료 요법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
US6165484A (en) 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
AUPP146598A0 (en) * 1998-01-21 1998-02-12 Health And Hygiene International Pty Ltd Fruit and vegetable wash
DE19921794A1 (de) * 1999-05-11 2000-11-23 Hexal Ag Neue pharmazeutische Zusammensetzung
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
JP4803511B2 (ja) * 2000-08-25 2011-10-26 株式会社ポーラファルマ 抗真菌医薬組成物
CN1678277B (zh) * 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
JP2005538156A (ja) * 2002-09-05 2005-12-15 ガルデルマ・ソシエテ・アノニム 爪塗布用溶液
WO2006013963A1 (ja) * 2004-08-05 2006-02-09 Hisamitsu Pharmaceutical Co., Inc. 爪用外用剤
US20060078599A1 (en) 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
JP4992181B2 (ja) * 2004-12-28 2012-08-08 大正製薬株式会社 外用剤組成物
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
CN1939539A (zh) 2005-09-29 2007-04-04 瑞士商拜欧伊果公司 疣、指甲疾病、及指甲保养用之局部配方
AU2006332425A1 (en) 2006-01-02 2007-07-12 Tlt Medical Ltd. Pharmaceutical composition for the treatment of nail diseases
US20070243222A1 (en) * 2006-02-03 2007-10-18 Carl Lawyer Fungicidal formulation and method of use
WO2007094999A2 (en) * 2006-02-13 2007-08-23 Stiefel Laboratories, Inc. Ungual antifungal compositions
US20080038219A1 (en) 2006-08-07 2008-02-14 Calgenex Corporation Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
AU2007355106A1 (en) * 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
CN105125529A (zh) * 2007-02-05 2015-12-09 亲生物有限公司 烯丙胺药物化合物的增加的效力
WO2008121709A1 (en) 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
JP2011529038A (ja) * 2008-07-23 2011-12-01 ターゲッティド デリバリー テクノロジーズ リミテッド 真菌感染症の処置のための局所抗真菌製剤の投与方法
US8524258B2 (en) * 2008-12-22 2013-09-03 Johnson & Johnson Consumer Companies, Inc. Structured lotions
FR2942716B1 (fr) * 2009-03-06 2011-04-15 Galderma Res & Dev Methode de solubilisation d'agent antifongique et compositions a haute concentration en agent antifongique applicables sur l'ongle
BR112012003209A2 (pt) * 2009-08-13 2016-03-01 Moberg Derma Ab composições e métodos para tratar infecção fúngica da unha
AU2010336441B2 (en) * 2009-12-23 2015-02-05 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
WO2012017371A1 (en) * 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, clobetasole propionate, terbinafine hydrochloride and a process to make it
PL2672962T3 (pl) 2011-02-11 2015-08-31 Moberg Pharma Ab Nowa kompozycja przeciwgrzybicza

Also Published As

Publication number Publication date
SG192615A1 (en) 2013-09-30
PT2672962E (pt) 2015-05-25
SI2672962T1 (sl) 2015-06-30
SMT201500154B (it) 2015-09-07
JP5883886B2 (ja) 2016-03-15
JP2014508146A (ja) 2014-04-03
ZA201305891B (en) 2015-06-24
RU2587064C2 (ru) 2016-06-10
EP2672962A1 (en) 2013-12-18
US8952070B2 (en) 2015-02-10
RU2013136147A (ru) 2015-03-20
AU2012215383B2 (en) 2016-06-09
IL227765A (en) 2016-09-29
CA2826741C (en) 2016-03-29
MX2013009245A (es) 2013-12-09
CN103384518A (zh) 2013-11-06
US20150250878A1 (en) 2015-09-10
EP2672962B1 (en) 2015-03-25
CA2826741A1 (en) 2012-08-16
ES2535827T3 (es) 2015-05-18
AU2012215383A1 (en) 2013-08-29
KR20140025341A (ko) 2014-03-04
CN109453150A (zh) 2019-03-12
CN103384518B (zh) 2018-10-26
KR101647545B1 (ko) 2016-08-10
MX335945B (es) 2016-01-04
ME02152B (me) 2015-10-20
US20170258914A1 (en) 2017-09-14
PL2672962T3 (pl) 2015-08-31
DK2672962T3 (en) 2015-04-20
RS53982B1 (sr) 2015-10-30
BR112013020456B1 (pt) 2020-01-21
WO2012107565A1 (en) 2012-08-16
US20140031430A1 (en) 2014-01-30
BR112013020456A2 (pt) 2016-10-18
US9561279B2 (en) 2017-02-07
HK1190944A1 (en) 2014-07-18
HRP20150507T1 (hr) 2015-06-19
IL227765A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1122358T1 (el) C-τελικοι hsp90 αναστολεις
HUE069570T2 (hu) Nitril-tartalmú vegyületek gyógyszerként történõ alkalmazásra
CY1120104T1 (el) Αναστολεις της syk
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
CY1125100T1 (el) Υδατικο φαρμακευτικο σκευασμα ταπενταδολης για απο του στοματος χορηγηση
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
CY1120796T1 (el) Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CL2013003450A1 (es) Composicion que contiene oxintomodulina, un polimero de polietilenglicol y 9-fluorenilmetoxicarbonilo o 2-sulfo-9-fluorenilmetoxicarbonilo; metodos de uso.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
PE20140252A1 (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CY1125157T1 (el) Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
MX335945B (es) Composicion antifungica novedosa.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
JOP20170123A1 (ar) مركبات كارفيلزوميب بيجيلية
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BR112014002758A2 (pt) composições para cuidados pessoais contendo zinco piritiona submetido à secagem
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CY1116559T1 (el) Νεα φαρμακευτικη συνθεση για την αγωγη μυκητιασικων λοιμωξεων